Finally, a phase I clinical report of mogamulizumab in combination with anti-PD-1 treatment in patients with advanced or metastatic solid tumors has found a clear depletion of effector Tregs and tumor-infiltrating CD8+ expansion. This evidence concerns the gene CD8A and neoplasm.